Journal article

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A Ledermann, Ursula A Matulonis, Amit M Oza, Ilan Bruchim, Tomasz Huzarski, Charlie Gourley, Philipp Harter, Ignace Vergote, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tsveta Milenkova, Eric Pujade-Lauraine, Val Gebski, Chee K Lee

EUROPEAN JOURNAL OF CANCER | ELSEVIER SCI LTD | Published : 2021

Abstract

BACKGROUND: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely. Individual prognostic factors do not reliably distinguish patients who progress early from those who have durable benefit. We developed and validated a prognostic nomogram to predict PFS in these patients. METHODS: The nomogram was developed using data from a training patient cohort with BRCA mutations and high-grade serous PSROC on the placebo arm of two maintenance therapy trials, Study 19 and SOLO2/ENGOT-ov21. We performed multivariable Cox regression analysis based on pre-treatm..

View full abstract

Grants

Funding Acknowledgements

This work was supported by AstraZeneca. This work was written by the authors with no medical writing support, input or other involvement by the funder.